News Archive

Optivia Offers Certified GenoMembrane Efflux Transporter Vesicles

Optivia Biotechnology now offers certified GenoMembrane transporter vesicle products in the US and Canada High-quality “inside-out” vesicles for studying ATP-Binding Cassette (ABC) transporters including BSEP, MRPs, MDR1 and BCRP (Santa Clara, CA | March 8, 2017) Optivia is pleased to announce its partnership with GenoMembrane Co. LTD. (Japan), a leading provider of high-quality, “inside-out” efflux(…)

Optivia Launches TransFlex™ Assay-Ready Plates

TransFlex™ Assay-Ready Transporter Plates Now Available · Ready to use – receive your plate, get data the next day ·  Suitable for both substrate and inhibition studies ·  Available for a variety of single-transporter and multi-transporter models ·  Easy to use 96-well format ·  Flexible plate configurations allow multiple transporter options plus control cells on the same plate ·(…)

Optivia Biotechnology and The Sugiyama Laboratory/RIKEN Sign Collaborative Agreement

Optivia Biotechnology and The Sugiyama Laboratory/RIKEN Sign Collaborative Agreement Leading transporter research groups to standardize in vitro transporter studies and collaborate on drug-drug interaction modeling Menlo Park, CA and Yokahama, Japan October 7, 2015 – Optivia Biotechnology and the Sugiyama Lab at RIKEN have entered into a collaborative agreement to develop a dynamic, multi-scale, physiologically(…)

Optivia Biotechnology Launches Screening Service for Transporters as Drug Targets

Optivia Biotechnology Launches Screening Service for Transporters as Drug Targets Opti-Target™ Screening Service Facilitates the Discovery of New Classes of Therapeutics Targeting Membrane Transporters MENLO PARK, CA (BUSINESS WIRE) September 15, 2015—Optivia Biotechnology Inc., a leading global provider of high-quality transporter assay services and innovative transporter research solutions, announces the launch of its Opti-Target™ Transporter Screening(…)

Optivia Biotechnology Inc and Rhenovia Pharma Sign Partnership Agreement

OPTIVIA BIOTECHNOLOGY AND RHENOVIA PHARMA SIGN A PARTNERSHIP AGREEMENT Companies agree to partner to expand product and service offerings for better understanding drug’s effects in brain. Menlo Park, CA, Mulhouse, France, Cambridge, MA (PRWEB) May 20, 2015 – Optivia Biotechnology, the leading provider of high quality transporter assay services for Drug-Drug Interactions (DDI), Metabolism and(…)

Optivia Publishes Paper with Incyte Corporation

Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Zhang Y, et al. Drug Metab Dispos. 2015. Authors Zhang Y1, Warren MS2, Zhang X2, Diamond S2, Williams B2, Punwani N2, Huang J2, Huang Y2, Yeleswaram S2. Author information 1Incyte Corporation, Wilmington, Delaware (Y.Z., S.D., B.W., N.P., S.Y.), and Optivia Biotechnology, Menlo Park, California (M.W., X.Z.,(…)

Optivia Forms Technology & Marketing Alliance with Hurel

OPTIVIA BIOTECHNOLOGY FORMS TECHNOLOGY & MARKETING ALLIANCE WITH HUREL CORPORATION Firms partner to improve understanding of in vitro/in vivo correlation for transporter-mediated hepatic clearance, drug-drug interactions, and drug-induced liver injury